Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Investigating Treatment for High-Risk Breast Cancer
Clinical Breakthroughs

Investigating Treatment for High-Risk Breast Cancer

By Anna WilliamsOct 26, 2018
Share
Facebook Twitter Email
William Gradishar, MD, chief of Hematology and Oncology in the Department of Medicine and deputy director of the clinical network of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a co-author of the study published in the Journal of Clinical Oncology.

A drug called bevacizumab added to adjuvant chemotherapy did not improve outcomes for patients with a form of high-risk breast cancer, according to results of a clinical trial published in the Journal of Clinical Oncology.

William Gradishar, MD, chief of Hematology and Oncology in the Department of Medicine and deputy director of the clinical network of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a co-author of the study.

Bevacizumab is a drug that inhibits the growth of new blood vessels, which is known to play a key role in breast cancer progression.

In prior clinical trials, bevacizumab had been shown to improve progression-free survival — although not overall survival — when combined with chemotherapy in patients with metastatic breast cancer classified as HER2-negative. (HER2-negative indicates that tumors lack overexpression of the human epidermal growth factor receptor 2, a protein that promotes the growth of cancer cells; such a cancer would therefore not respond to drugs that target HER2.)

In the current study, the investigators hypothesized that bevacizumab would be most clinically effective when used in the adjuvant setting, when patients with breast cancer who have undergone surgery receive additional therapy to reduce the risk of recurrence.

The phase III trial included 4,994 patients with high-risk, HER2-negative breast cancer who were randomized to receive bevacizumab or a placebo while also undergoing adjuvant chemotherapy regimens.

The investigators found that bevacizumab added to adjuvant chemotherapy did not improve invasive disease-free survival or overall survival in the study population. There was also a high rate of early discontinuation with bevacizumab, which may indicate an unwillingness of patients and physicians to accept bevacizumab toxicities.

Bevacizumab blocks vascular endothelial growth factor (VEGF), a protein which helps cancers grow blood vessels. The authors note that other clinical trials that have similarly investigated targeting VEGF in the context of melanoma, colon cancer, lung cancer and HER2-positive breast cancer have also had negative findings.

“We have no choice but to conclude that the underlying hypothesis, namely that inhibiting VEGF would be most effective in the adjuvant setting, is simply wrong,” the authors wrote.

Gradishar is also the Betsy Bramsen Professor of Breast Oncology and director of the Maggie Daley Center for Women’s Cancer Care.

Read more:

  • Lurie Cancer Center Earns Exceptional Rating from National Cancer Institute
  • Drug Regimen Boosts Outcomes for Some Breast Cancer Patients
  • Scientists Examine Epigenetics of Breast Cancer

The study was supported by National Institutes of Health grants No. CA180820, CA180794, CA180790, CA180791, CA180795, CA180799, CA180802, CA180816, CA180821, CA180844, CA180847, CA189830, CA189859 and CA189863, the Breast Cancer Research Foundation and Susan G. Komen Foundation.

Cancer Research Women's Health
Share. Facebook Twitter Email

Related Posts

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.